Skip to main content

Table 3 Annual eGFR decline (ΔeGFR) in ADPKD patients according to the presence of hyperuricemia *

From: Hyperuricemia and deterioration of renal function in autosomal dominant polycystic kidney disease

 

Group A†(n = 255)

Group B‡(n = 41)

p-value

Mean sUA level (mg/dL)

4.69 ± 1.08

7.61 ± 0.95

< 0.001

F/U time (months)

73.0 ± 42.2

62.0 ± 46.8

0.134

Initial eGFR (mL/min/1.73 m2)

82.0 ± 19.6

52.2 ± 27.4

< 0.001

Final eGFR (mL/min/1.73 m2)

75.6 ± 27.9

48.3 ± 31.7

< 0.001

ΔeGFR (mL/min/1.73 m2/yr)

−0.29 ± 4.22

−1.87 ± 3.30

0.026

ΔeGFR (%/yr)

−0.72 ± 6.03

−6.23 ± 9.84

0.001

ESRD progression, n (%)

14 (5.4%)

14 (34.1%)

< 0.001

  1. *A total of 296 patients without hypouricemic medications were included in the analysis. †Group A: sUA < 7.0 mg/dL (Male) or < 6.0 mg/dL (Female), ‡Group B: sUA ≥ 7.0 mg/dL (Male) or ≥ 6.0 mg/dL. sUA, serum uric acid; ADPKD, autosomal dominant polycystic kidney disease; F/U, follow-up; eGFR, estimated glomerular filtration rate; ESRD, end-stage renal disease.
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us